Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal...

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Epithelial ovarian cancer has a poor prognosis, necessitating novel therapeutic strategies.
• Targeted therapies, particularly poly [ADP-ribose] polymerase (PARP) inhibitors, have emerged as significant advancements.
• PARP inhibitors are crucial in maintenance treatment and are under continuous investigation for combination therapies.

Purpose of the Study:

• To highlight the role of PARP inhibitors in treating gynecological malignancies.
• To introduce pamiparib, a new selective PARP-1 and PARP-2 inhibitor.
• To report the initial global registration of pamiparib in China.

Main Methods:

• Review of existing literature on PARP inhibitors in gynecological cancers.
• Identification of FDA-approved PARP inhibitors and their indications.
• Summary of pamiparib's development and regulatory status.

Main Results:

• Four PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) are FDA-approved for various cancers.
• Olaparib and rucaparib have expanded approvals for pancreatic and prostate cancers.
• Pamiparib received its first worldwide approval in China for recurrent ovarian, fallopian tube, or primary peritoneal cancer with germline BRCA mutation.

Conclusions:

• PARP inhibitors represent a significant therapeutic advance in ovarian cancer.
• Pamiparib's approval marks a milestone for this new targeted therapy.
• Further research into PARP inhibitor combinations is ongoing and essential.